May. 13 at 2:43 PM
$GALT Let the drug speaks for itself. The miss in per protocol was because many of patients missed the checkup during COVID. The FDA are the smart scientists who can see that issue and they will make a right decision. It will get approved to bring this drug to patients ASAP! JMO.
“These findings provide clinically meaningful evidence for the potential role of belapectin in addressing portal hypertension and reducing the risk of clinically significant complications in patients with MASH cirrhosis,” said Prof. Naga Chalasani, David W. Crabb Professor of Gastroenterology and Hepatology at Indiana University School of Medicine and principal investigator for the NAVIGATE program. “The observed reduction in variceal development, together with consistent biomarker findings and a favorable safety profile, supports continued development of belapectin in patients with MASH cirrhosis and portal hypertension—a population with substantial unmet medical need.”
